A functional precision medicine study conducted in Finland demonstrates that treatment selection based on results from drug sensitivity testing of patients’ cells can be clinically useful in patients with aggressive hematological cancers.
A functional precision medicine study conducted in Finland demonstrates that treatment selection based on results from drug sensitivity testing of patients’ cells can be clinically useful in patients with aggressive hematological cancers.